Customer Support

Contact our support team if you have any enquiries about any of our products

Call: (856) 848-8698


Particle Immuno-Filtration Assay (PIFA®) Technology

PIFA® technology is a cutting-edge, patented immunoassay method which rapidly, easily, and accurately detects target antigens or antibodies.

How It Works

PIFA® technology is based on the selective filtration of microparticles in response to antibody/antigen binding. Dyed microparticles coated with antigens or antibodies determine the visual signal for the results of the assay. The presence of a corresponding antibody or antigen in the test sample results in the formation of a matrix of microparticles, which are more susceptible to filtration. The inability of these matrixed microparticles to move through the filter, and the resulting color change in the reagent mixture, signal positive reactivity of the test sample (e.g. the presence of target antigens or antibodies).

Key features of PIFA® technology make it advantageous for a broad array of uses:

  • Accuracy rivaling or surpassing current laboratory methods
  • Rapid Results, typically within 1 to 5 minutes
  • Point-of-care compatibility
  • Easy to use
  • Easy to dispose

PIFA® technology is currently used in commercially available and/or developmental tests for:

  • Coagulation disorders
  • Heparin allergy
  • Sexually transmitted infections (chlamydia)
  • Other infectious diseases (blood-borne pathogens)

Licensing Availability

PIFA® technology is available for licensing. To inquire about licensing or for technical inquiries, please contact us.

Patent Information

Akers Biosciences, Inc. holds patents related to PIFA® Technology.

U.S. patent nos. 5,565,366, 5,827,749, and 7,896,167; other patents pending.